浙江医药(600216) - 2025 Q2 - 季度业绩预告

Core Performance Forecast Data The company forecasts H1 2025 net profit attributable to shareholders to be RMB 600-720 million, a 90.28%-128.33% increase, with non-recurring adjusted net profit at RMB 590-708 million, up 86.27%-123.53% H1 2025 Performance Forecast | Metric | Estimated Amount (RMB Million) | YoY Growth | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 600.00 - 720.00 | 90.28% - 128.33% | | Net Profit After Non-Recurring Items | 590.00 - 708.00 | 86.27% - 123.53% | Prior Period Performance Review In H1 2024, the company reported RMB 315.33 million in net profit attributable to shareholders, RMB 316.74 million in non-recurring adjusted net profit, and RMB 0.33 in basic earnings per share, serving as the basis for this forecast H1 2024 (Prior Period) Performance | Metric | Amount (RMB) | | :--- | :--- | | Total Profit | 334.59 million | | Net Profit Attributable to Parent Company Shareholders | 315.33 million | | Net Profit After Non-Recurring Items | 316.74 million | | Earnings Per Share | 0.33 | Analysis of Performance Increase Drivers The significant performance increase is primarily driven by the company's life nutrition products segment, which saw robust market demand and rising sales prices for its main products, boosting overall revenue and profit - The primary driver for performance growth is the life nutrition products segment, with increased market demand and sales prices for its leading products compared to the prior year, leading to higher sales revenue[6] Risk Warning and Other Disclosures The company states that this performance forecast is based on unaudited preliminary calculations, with final accurate financial data subject to the official H1 2025 report, and confirms no material uncertainties affecting the forecast's accuracy - This performance forecast data is unaudited and preliminary, investors should refer to the company's officially disclosed H1 2025 semi-annual report for final figures[7][8] - The company declares no material uncertainties exist that would affect the accuracy of this performance forecast[7]